The Cigna Group (CI)
Here's Why Cigna (CI) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can Cigna's Smart Coverage Help Close Health-Cost Gaps?
CI's Smart Coverage links medical and supplemental benefits, offering up to $7,000 and automated claims for costly health events.
Beneath the Headlines: An Economy in Transition, Not in Trouble
Key Takeaways The July jobs report headline (-23,000 payrolls and a combined -103,000 in prior-month revisions) glances over a more nuanced picture: layoffs remain historically low and job openings remain plentiful. This looks like a labor-supply problem, not a demand setback.
5 HMO Stocks to Watch Amid Steady Premium Flow, Increased Digitization
An aging U.S. population, digital transformation, a diversified membership mix and strategic M&A are likely to drive the performance of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.
Cigna (CI) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Stay Neutral on Cigna Stock for Now
CI's growth and shareholder returns are weighed against rising costs, medical expenses and debt, keeping investors neutral for now.
Cigna: I'm Buying What Others Are Ignoring
Cigna Group remains a "Buy," with double-digit adjusted EPS growth intact and shares trading 28% below fair value. CI's Accredo and AI-powered Pharmacy Forward platforms are key growth drivers, supporting robust revenue and margin expansion through 2028. The company boasts an A- S&P credit rating, strong free cash flow, and a secure, growing dividend with low payout ratios.
Why Cigna (CI) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Cigna (CI) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cigna's Valuation Gap Still Stands Out
Cigna (CI) maintains a Buy rating as valuation remains deeply discounted despite steady earnings growth and raised guidance. CI lifted 2026 adjusted EPS guidance to at least $30.45, targeting 10% EPS growth and mid-single-digit revenue growth through 2027. Capital returns continue with $6.3 billion in cash, ongoing buybacks, and a $1.56 per share dividend, supported by strong operating cash flow.
Cigna Group Q2 Earnings Call Highlights
Cigna Group NYSE: CI raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that management said exceeded expectations in both its Evernorth health services business and Cigna Healthcare insurance segment.
CI Q2 Earnings Beat Estimates on Cigna Healthcare Strength
Cigna delivers an earnings and revenue beat as Cigna Healthcare fuels growth, while the company raises its 2026 EPS outlook despite higher pharmacy costs.
